[Epidemiology of SARS-CoV-2 infection and COVID-19].

Epidemiologie von SARS-CoV-2-Infektion und COVID-19.

Journal

Der Internist
ISSN: 1432-1289
Titre abrégé: Internist (Berl)
Pays: Germany
ID NLM: 0264620

Informations de publication

Date de publication:
Aug 2020
Historique:
pubmed: 18 6 2020
medline: 6 8 2020
entrez: 18 6 2020
Statut: ppublish

Résumé

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is a new β‑Coronavirus that was first detected in 2019 in Wuhan, China. In the ensuing months it has been transmitted worldwide. Here the authors present the current knowledge on the epidemiology of this virus. SARS-CoV‑2 replicates mainly in the upper and lower respiratory tract and is primarily transmitted by droplets from asymptomatic and symptomatic infected subjects. The estimate for the basic reproduction number (R) is currently between 2 and 3, while the incubation period is 6 (median, range 2-14) days. Although most infections are uncomplicated, 5-10% of cases develop pneumonia, which can lead to hospitalization, respiratory failure and multiorgan failure. Risk factors for a complicated disease course include age, hypertension, chronic cardiovascular and pulmonary disease and immunodeficiency. The overall case fatality rate is 1.4%, with the rate rising in the sixth decade of life. Nosocomial and infections in medical personnel have been reported. Drastic reductions in social contact have been implemented in many countries with outbreaks of SARS-CoV‑2, leading to rapid reductions in R. Which of the measures have been effective is still unknown.

Identifiants

pubmed: 32548652
doi: 10.1007/s00108-020-00834-9
pii: 10.1007/s00108-020-00834-9
pmc: PMC7296906
doi:

Types de publication

Journal Article Review

Langues

ger

Sous-ensembles de citation

IM

Pagination

782-788

Références

N Engl J Med. 2020 Mar 26;382(13):1199-1207
pubmed: 31995857
N Engl J Med. 2020 Apr 30;382(18):1708-1720
pubmed: 32109013
Science. 2020 May 1;368(6490):489-493
pubmed: 32179701
Lancet. 2020 Feb 29;395(10225):689-697
pubmed: 32014114
China CDC Wkly. 2020 Feb 21;2(8):113-122
pubmed: 34594836
Ann Intern Med. 2020 May 05;172(9):577-582
pubmed: 32150748
Bull Math Biol. 2020 Apr 8;82(4):52
pubmed: 32270376
Nature. 2020 May;581(7809):465-469
pubmed: 32235945
Lancet Infect Dis. 2020 Jun;20(6):669-677
pubmed: 32240634
J Travel Med. 2020 May 18;27(3):
pubmed: 32109273

Auteurs

B Salzberger (B)

Abt. Krankenhaushygiene und Infektiologie, Universitätsklinikum Regensburg, Franz-Josef-Strauß-Allee 11, 93053, Regensburg, Deutschland. bernd.salzberger@ukr.de.

F Buder (F)

Abt. Krankenhaushygiene und Infektiologie, Universitätsklinikum Regensburg, Franz-Josef-Strauß-Allee 11, 93053, Regensburg, Deutschland.

B Lampl (B)

Sachgebiet Infektionsschutz und Hygiene, Gesundheitsamt Regensburg, Regensburg, Deutschland.

B Ehrenstein (B)

Klinik und Poliklinik für Rheumatologie und Klinische Immunologie, Fachklinikum Bad Abbach, Bad Abbach, Deutschland.

F Hitzenbichler (F)

Abt. Krankenhaushygiene und Infektiologie, Universitätsklinikum Regensburg, Franz-Josef-Strauß-Allee 11, 93053, Regensburg, Deutschland.

F Hanses (F)

Abt. Krankenhaushygiene und Infektiologie, Universitätsklinikum Regensburg, Franz-Josef-Strauß-Allee 11, 93053, Regensburg, Deutschland.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH